関連する実験動画
Updated: Jul 19, 2026

08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
心房内ナトリウレチンペプチドが,筋肉の交感活動と,人間の心不全におけるその反射制御に与える影響
B L Abramson1, S Ando, C F Notarius
1Divisions of Cardiology, the Toronto Hospital and Mount Sinai Hospital, and the Centre for Cardiovascular Research, University of Toronto.
Circulation
|April 13, 1999
まとめ
心房内ナトリウレチンペプチド (ANP) は,下部体負圧 (LBNP) の間でも,心不全患者の筋肉交感神経活動 (MSNA) を抑制します. この交感抑制効果は,心房圧が全身血圧に影響を与えることなく低下すると明らかになる.
科学分野:
- 心血管生理学 心血管の生理学
- 神経内分泌学の神経内分泌学
- 心不全 病理生理学 心不全 病理生理学
背景:
- 心不全は,交感神経系の活動の変化と関連しています.
- アトリアルナトリウレチンペプチド (ANP) は,血管拡張性およびナトリウレチンの作用が知られているホルモンです.
- 心不全における同情神経活動に対するANPの効果は完全に理解されていません.
研究 の 目的:
- 心不全患者のANPのシンパト抑制効果を調査する.
- ANPが静止状態と下部体負圧 (LBNP) 中の筋肉交感神経活動 (MSNA) を調節するかどうかを判断する.
主な方法:
- 拡張性心筋症を持つ15人の男性は,対照群としてANPとニトログリセリン (NTG) の静脈注入を受けた.
- 血圧 (BP),中央静脈圧 (CVP),心拍数 (HR) を含む血液動力学的パラメータが監視されました.
- 筋肉の交感神経活動 (MSNA) は,休息状態とLBNP (−6および−12 mm Hg) の間に記録されました.
主要な成果:
- ANPとNTGの両方が,CVPと腹動脈BPを同様の方法で減少させた.
- 休息中のMSNAは,いずれの輸注でも増加しませんでした.
- LBNPはCVPとBPの減少を誘発し,ANPとNTGでは同様の効果がありました.
- MSNAは,静止状態とLBNPの間,ANP輸液中に有意に低下しました.
- 非潜在的LBNPは,NTG中にMSNAが増加したが,ANPでは増加しなかった.
結論:
- ANPは,心不全の患者に同情抑制作用を発揮する.
- この効果は,ANPが全身血圧を変えることなく心房圧を下げるときに最も顕著です.
- ANPは,心不全における交感性過剰活性を調節する役割を果たす可能性があります.
さらに関連する動画
関連する概念動画
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

